Prognostic significance of MGMT promoter methylation in diffuse glioma patients

Figures & data

Figure 1. MRI imaging of a patient who underwent total resection and treatment with TMZ before (A) and after (B) the operation.

Table 1. Distribution of glioma subtypes in the study group.

Diagnosis	ICD-O	Number of patients (n = 33)
Glioblastoma	9440/3	29^a
Anaplastic astrocytoma	9401/3	1
Oligoastrocytoma	9382/3	2
Oligodendroglioma	9450/3	1

^aFour out of 29 samples were recurrent glioblastoma.

Figure 2. MSP amplification of the MGMT promoter CpG region using a methylated (M) and an unmethylated (U) set of primers; lanes 8–27, methylated and bisulphite converted DNA isolated from tumour samples.

Table 2. Clinical characteristics and survival data.

	Unmethylated MGMT (n = 16)	Methylated MGMT (n = 17)	OS (median)
<50 yr	5 (31.25%)	3 (17.65%)	19 months
>50 yr	11 (68.75%)	14 (82.35%)	7 months
Total resection	9 (56.25%)	5 (29.41%)	11 months
Partial resection	4 (25.00%)	7 (41.17%)	7 months
Biopsy	3 (18.75%)	5 (29.41%)	1.5 months
Age	58.5 ± 12.1380	60.705 ± 8.219
Male	10 (62.5%)	11 (64.7%)
Female	6 (37.5%)	6 (35.3%)

Table 3. Comparison of survival distributions (log-rank test).

	Log-rank test statistic	P
>50 years age group	−3.50871	0.00045
<50 years age group
Male	−1.00520	0.31480
Female
Unmethylated MGMT	0.3098105	0.75671
Methylated MGMT
Maximum resection	−1.59104	0.11160
Partial resection
Maximum resection	−2.34768	0.01889
Biopsy
Partial resection	−1.91236	0.05583
Biopsy

Figure 3. Kaplan–Meier estimates of overall survival (months) related to age (A), gender (B), MGMT promoter methylation status (C) and type of resection (D).